GlycoMimetics, Inc. GKO.F Stock
GlycoMimetics, Inc. Price Chart
GlycoMimetics, Inc. GKO.F Financial and Trading Overview
GlycoMimetics, Inc. stock price | 0.26 EUR |
Previous Close | 1.61 EUR |
Open | 1.72 EUR |
Bid | 1.72 EUR x 100000 |
Ask | 1.77 EUR x 100000 |
Day's Range | 1.72 - 1.72 EUR |
52 Week Range | 0.51 - 3.72 EUR |
Volume | 10K EUR |
Avg. Volume | 789 EUR |
Market Cap | 110.72M EUR |
Beta (5Y Monthly) | 2.095422 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.54 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.67 EUR |
GKO.F Valuation Measures
Enterprise Value | 40.37M EUR |
Trailing P/E | N/A |
Forward P/E | -1.2947367 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 1476.2821 |
Price/Book (mrq) | 1.7789257 |
Enterprise Value/Revenue | 538.265 |
Enterprise Value/EBITDA | -0.928 |
Trading Information
GlycoMimetics, Inc. Stock Price History
Beta (5Y Monthly) | 2.095422 |
52-Week Change | 209.88% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.72 EUR |
52 Week Low | 0.51 EUR |
50-Day Moving Average | 1.46 EUR |
200-Day Moving Average | 1.54 EUR |
GKO.F Share Statistics
Avg. Volume (3 month) | 789 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 64.25M |
Float | 39.5M |
Short Ratio | N/A |
% Held by Insiders | 2.62% |
% Held by Institutions | 54.46% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -58245.63% |
Gross Margin | 100.00% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -36.31% |
Return on Equity (ttm) | -65.11% |
Income Statement
Revenue (ttm) | 75K EUR |
Revenue Per Share (ttm) | 0.001 EUR |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 75K EUR |
EBITDA | -43492552 EUR |
Net Income Avi to Common (ttm) | -42395112 EUR |
Diluted EPS (ttm) | -0.7 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 65M EUR |
Total Cash Per Share (mrq) | 1.01 EUR |
Total Debt (mrq) | 651.73K EUR |
Total Debt/Equity (mrq) | 1.05 EUR |
Current Ratio (mrq) | 10.102 |
Book Value Per Share (mrq) | 0.968 |
Cash Flow Statement
Operating Cash Flow (ttm) | -44366204 EUR |
Levered Free Cash Flow (ttm) | -31311240 EUR |
Profile of GlycoMimetics, Inc.
Country | Germany |
State | MD |
City | Rockville |
Address | 9708 Medical Center Drive |
ZIP | 20850 |
Phone | 240 243 1201 |
Website | https://www.glycomimetics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 38 |
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Q&A For GlycoMimetics, Inc. Stock
What is a current GKO.F stock price?
GlycoMimetics, Inc. GKO.F stock price today per share is 0.26 EUR.
How to purchase GlycoMimetics, Inc. stock?
You can buy GKO.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for GlycoMimetics, Inc.?
The stock symbol or ticker of GlycoMimetics, Inc. is GKO.F.
Which industry does the GlycoMimetics, Inc. company belong to?
The GlycoMimetics, Inc. industry is Biotechnology.
How many shares does GlycoMimetics, Inc. have in circulation?
The max supply of GlycoMimetics, Inc. shares is 64.46M.
What is GlycoMimetics, Inc. Price to Earnings Ratio (PE Ratio)?
GlycoMimetics, Inc. PE Ratio is now.
What was GlycoMimetics, Inc. earnings per share over the trailing 12 months (TTM)?
GlycoMimetics, Inc. EPS is -0.54 EUR over the trailing 12 months.
Which sector does the GlycoMimetics, Inc. company belong to?
The GlycoMimetics, Inc. sector is Healthcare.